W e note with interest the theme of "Tuberculosis (TB)" for this issue of the Western Pacific Surveillance and Response Journal and wish to share our experiences in investigating suppurative lymphadenitis as a result of the Bacille-Calmette-Guérin (BCG) vaccine in Hong Kong (China).
The TB notification rate in Hong Kong (China) has been decreasing in the past 50 years from a peak of 697 per 100 000 in 1952 to 72.5 per 100 000 in 2010. The number of TB notifications in Hong Kong (China) in 2010 was 5093.
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The BCG vaccine for the prevention of TB was developed almost 100 years ago and use of the vaccine commenced in Hong Kong (China) in 1952. The vaccine protects children against severe forms of TB such as TB meningitis and miliary TB. To assess the trend of hospitalized BCG lymphadenopathy in recent years, we reviewed records of patients hospitalized between 1 January 2004 and 31 December 2012 with relevant ICD-9 code diagnoses of BCG-related adverse effects and lymphadenopathy from all public hospitals in Hong Kong (China). Public hospitals account for around 80% of secondary and tertiary care in Hong Kong (China). 
